Table 1.
Clinical, pathologic, demographic and molecular characteristics of the studied EGFR mutated patients
| Characteristic | no. of patients | % | |
|---|---|---|---|
| Age (years) | |||
| Median | 65 | ||
| Range | 55-86 | ||
| Sex | |||
| Female | 5 | 71.5 | |
| Male | 2 | 28.5 | |
| Smoking history | |||
| Never smoker | 1 | 14.2 | |
| Former smoker | 5 | 71.5 | |
| Current smoker | 1 | 14.2 | |
| Histology | |||
| Adenocarcinoma | 6 | 85.7 | |
| NSCLC – NOS | 1 | 14.2 | |
| EGFR mutation | |||
| Exon 19 deletion* | 5 | 71.5 | |
| L858R | 2 | 28.5 | |
| Therapy prior to erlotinib | |||
| Platinum-based chemotherapy | 2 | 28.5 | |
| No prior therapy | 5 | 71.5 | |
no., number; NSCLC-NOS, non-small cell lung cancer-non otherwise specified;
*
specific EGFR sequences of the exon 19 deletions are detailed in Table 2.